112 related articles for article (PubMed ID: 2823606)
1. Long-term intracaval calcium infusion therapy in end-organ resistance to 1,25-dihydroxyvitamin D.
Weisman Y; Bab I; Gazit D; Spirer Z; Jaffe M; Hochberg Z
Am J Med; 1987 Nov; 83(5):984-90. PubMed ID: 2823606
[TBL] [Abstract][Full Text] [Related]
2. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.
Harrell RM; Lyles KW; Harrelson JM; Friedman NE; Drezner MK
J Clin Invest; 1985 Jun; 75(6):1858-68. PubMed ID: 3839245
[TBL] [Abstract][Full Text] [Related]
3. The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII).
al-Aqeel A; Ozand P; Sobki S; Sewairi W; Marx S
Clin Endocrinol (Oxf); 1993 Aug; 39(2):229-37. PubMed ID: 8396512
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
Drezner MK; Lyles KW; Haussler MR; Harrelson JM
J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
[TBL] [Abstract][Full Text] [Related]
5. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D.
Balsan S; Garabédian M; Larchet M; Gorski AM; Cournot G; Tau C; Bourdeau A; Silve C; Ricour C
J Clin Invest; 1986 May; 77(5):1661-7. PubMed ID: 3009551
[TBL] [Abstract][Full Text] [Related]
6. Calcium therapy for calcitriol-resistant rickets.
Hochberg Z; Tiosano D; Even L
J Pediatr; 1992 Nov; 121(5 Pt 1):803-8. PubMed ID: 1331389
[TBL] [Abstract][Full Text] [Related]
7. Absent intestinal response to calciferols in hereditary resistance to 1,25-dihydroxyvitamin D: documentation and effective therapy with high dose intravenous calcium infusions.
Bliziotes M; Yergey AL; Nanes MS; Muenzer J; Begley MG; Vieira NE; Kher KK; Brandi ML; Marx SJ
J Clin Endocrinol Metab; 1988 Feb; 66(2):294-300. PubMed ID: 2828407
[TBL] [Abstract][Full Text] [Related]
8. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density.
Saggese G; Baroncelli GI; Bertelloni S; Perri G
J Pediatr; 1995 Sep; 127(3):395-402. PubMed ID: 7658269
[TBL] [Abstract][Full Text] [Related]
9. A familial syndrome of decrease in sensitivity to 1,25-dihydroxyvitamin D.
Marx SJ; Spiegel AM; Brown EM; Gardner DG; Downs RW; Attie M; Hamstra AJ; DeLuca HF
J Clin Endocrinol Metab; 1978 Dec; 47(6):1303-10. PubMed ID: 233695
[TBL] [Abstract][Full Text] [Related]
10. Renal hypophosphatemic rickets: growth acceleration after long-term treatment with 1,25-dihydroxyvitamin-D3.
Chan JC; Lovinger RD; Mamunes P
Pediatrics; 1980 Sep; 66(3):445-54. PubMed ID: 6893489
[TBL] [Abstract][Full Text] [Related]
11. Long-term influence of calcitriol (1,25-dihydroxyvitamin D) and supplemental phosphate in X-linked hypophosphatemic rickets.
Chesney RW; Mazess RB; Rose P; Hamstra AJ; DeLuca HF; Breed AL
Pediatrics; 1983 Apr; 71(4):559-67. PubMed ID: 6300745
[TBL] [Abstract][Full Text] [Related]
12. Hypercalciuric hypophosphatemic rickets, mineral balance, bone histomorphometry, and therapeutic implications of hypercalciuria.
Chen C; Carpenter T; Steg N; Baron R; Anast C
Pediatrics; 1989 Aug; 84(2):276-80. PubMed ID: 2787497
[TBL] [Abstract][Full Text] [Related]
13. Rickets and alopecia with resistance to 1,25-dihydroxyvitamin D: two different clinical courses with two different cellular defects.
Balsan S; Garabedian M; Liberman UA; Eil C; Bourdeau A; Guillozo H; Grimberg R; Le Deunff MJ; Lieberherr M; Guimbaud P; Broyer M; Marx SJ
J Clin Endocrinol Metab; 1983 Oct; 57(4):803-11. PubMed ID: 6309886
[TBL] [Abstract][Full Text] [Related]
14. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
15. 1 alpha-hydroxyvitamin D3 treatment of three patients with 1,25-dihydroxyvitamin D-receptor-defect rickets and alopecia.
Takeda E; Kuroda Y; Saijo T; Naito E; Kobashi H; Yokota I; Miyao M
Pediatrics; 1987 Jul; 80(1):97-101. PubMed ID: 3037475
[TBL] [Abstract][Full Text] [Related]
16. Hereditary resistance to 1,25-dihydroxyvitamin D: clinical and radiological improvement during high-dose oral calcium therapy.
Sakati N; Woodhouse NJ; Niles N; Harfi H; de Grange DA; Marx S
Horm Res; 1986; 24(4):280-7. PubMed ID: 3023230
[TBL] [Abstract][Full Text] [Related]
17. Osteomalacia in hereditary hypophosphatemic rickets with hypercalciuria: a correlative clinical-histomorphometric study.
Gazit D; Tieder M; Liberman UA; Passi-Even L; Bab IA
J Clin Endocrinol Metab; 1991 Jan; 72(1):229-35. PubMed ID: 1986023
[TBL] [Abstract][Full Text] [Related]
18. Oral calcium treatment in vitamin D-dependent rickets type II.
Wong GW; Leung SS; Law WY; Cheung NK; Oppenheimer SJ
J Paediatr Child Health; 1994 Oct; 30(5):444-6. PubMed ID: 7833085
[TBL] [Abstract][Full Text] [Related]
19. 1,25-Dihydroxyvitamin D resistance, rickets, and alopecia.
Hochberg Z; Benderli A; Levy J; Vardi P; Weisman Y; Chen T; Feldman D
Am J Med; 1984 Nov; 77(5):805-11. PubMed ID: 6548607
[TBL] [Abstract][Full Text] [Related]
20. Preliminary trials with 24,25-dihydroxyvitamin D3 in dialysis osteomalacia.
Hodsman AB; Wong EG; Sherrard DJ; Brickman AS; Lee DB; Singer FR; Norman AW; Coburn JW
Am J Med; 1983 Mar; 74(3):407-14. PubMed ID: 6338716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
